Survodutide

Mean weight change at week 76 was -12.2% (3.6 mg), -13.0% (6.0 mg), and -5.4% (placebo).; At least 5% weight reduction occurred in 72.6% (3.6 mg), 71.9% (6.0 mg), and 46.3% (placebo) of participants (P<0.001 vs placebo).; Gastrointestinal symptoms were the most common adverse events, occurring in 80.9% (3.6 mg), 89.7% (6.0 mg), and 47.9% (placebo) of participants; no deaths were reported.

84.2% of survodutide-treated patients vs 24.3% of placebo-treated patients achieved a 30% reduction in liver fat content (efficacy estimand; P < 0.0001); Mean body weight change was -12.2% with survodutide vs -1.0% with placebo (efficacy estimand; P < 0.0001); Most frequent adverse events with survodutide were gastrointestinal, commonly during dose escalation, and generally mild-to-moderate; Limitations included short trial duration (48 weeks) and recruitment limited to the United States and Spain

Next-generation agents engage GLP-1, GIP, glucagon, amylin, and peptide YY receptors to enhance energy uptake, storage, and expenditure.; Maridebart cafraglutide combines GLP-1 receptor agonism with GIP receptor antagonism, showing promise.; Glucagon coagonists like survodutide and mazdutide demonstrate significant weight loss and improved glycemic control.; Orally active small-molecule GLP-1 receptor agonists such as danuglipron and orforglipron are resistant to enzymatic degradation, advancing patient-friendly drug delivery.

Participants (n=725) had a mean BMI of 37.9 kg/m² and waist circumference of 115.2 cm.; Most participants were female (59.4%), with 47.3% from North America, 21.0% from Europe, and 20.0% from East Asia.; Common obesity complications at baseline included hypertension (40.0%), dyslipidaemia (33.7%), and prediabetes (30.2%).; Mean HbA1c was 5.5%, and 21.8% were taking lipid-lowering drugs.

Pegozafermin, cilofexor + firsocostat, and denifanstat were significantly better than placebo for fibrosis regression without MASH worsening.; Pegozafermin, survodutide, and tirzepatide were the most effective for MASH resolution without worsening fibrosis.; SUCRA rankings identified pegozafermin as top for both fibrosis regression (79.92) and MASH resolution (91.75).; Eight agents significantly improved fibrosis regression, while twelve agents significantly improved MASH resolution versus placebo.

Current therapies for DM and CKD encompass five drug classes: ACEI/AIIRB, SGLT2 inhibitors, GLP-1 RA, ET1R antagonists, and the MRA finerenone.; Finerenone has been tested in RCTs as a kidney protective agent.; Novel agents in development include balcinrenone, baxdrostat, vicadrostat, tirzepatide, survodutide, retatrutide, cagrilintide, zibotentan, and avenciguat.; Future strategies rely on integrated, patient-centered approaches and personalized therapy to curb renal disease and its complications.

GLP-1 receptor agonists (e.g., semaglutide) achieve 15-17% weight loss with a good safety profile.; Tirzepatide, a dual GLP-1/GIP agonist, achieves up to 22.5% weight loss at highest doses.; Combinations like Cagrisema and Retatrutide are expected to achieve similar weight loss ranges.; New drugs target gastroenteropancreatic hormones to improve cardiometabolic variables.

Retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), surpassing GLP-1RAs (-9.0 kg).; Retatrutide had the highest odds of achieving 15% weight loss (OR 54.6), followed by dual agonists (OR 16.4) and GLP-1RAs (OR 9.0).; Retatrutide had the highest adverse event risk, while dual agonists offered a favorable efficacy-safety balance.; Type 2 diabetes mellitus reduced weight loss by 4.338 kg for GLP-1RAs and 5.016 kg for dual agonists, with enhanced outcomes in female-dominant or high-BMI cohorts.

What is Survodutide?

**Mechanism of Action** Survodutide (BI 456906) is a synthetic dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R). By simultaneously activating both receptors, it enhances energy expenditure via glucagon-mediated thermogenesis and lipolysis while reducing appetite and delaying ga

How does Survodutide work?

Dual glucagon/GLP-1 receptor agonist in phase 3 for obesity and MASH.

What is the research status of Survodutide?

Survodutide is currently classified as clinical trials, with 88 research references on record. This is for research purposes only and is not medical advice.

What is the molecular weight of Survodutide?

Survodutide has a molecular weight of approximately 4232 g/mol (formula C192H289N47O61).